{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:14:27Z","timestamp":1784042067553,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["EV1-174804"],"award-info":[{"award-number":["EV1-174804"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["EV1-174804"],"award-info":[{"award-number":["EV1-174804"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In response to the ongoing drug toxicity crisis, driven by fentanyl and its analogues in the unregulated drug supply, Canada has funded several safer supply programs, which provide pharmaceutical-grade medications to reduce the reliance on toxic unregulated drug supply for people who use drugs. In this study, we examined barriers and facilitators that influenced the implementation of integrated safer supply pilot programs (ISSPP) across Canada.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between March 2022 and May 2023, we conducted a qualitative study using semi-structured interviews with key informants from ten ISSPP located in three provinces across Canada. Data analysis and interpretation of findings were guided by the Consolidated Framework for Implementation Research (CFIR). Thematic analysis was used to code transcripts and identify themes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>ISSPP varied greatly in the degree of ancillary and wraparound services provided. Additionally, differences existed across the ten programs in terms of eligibility criteria for enrolling clients and the availability of medication options. We found twelve constructs and three sub-constructs across four domains of CFIR that influenced the implementation of ISSPP. Implementation facilitators included low-barrier and client-centered delivery model, ongoing needs assessment through program monitoring and evaluation, integration of wraparound care, partnership with local services to coordinate client care, community buy-in, clinical protocols and standardized practices, and multidisciplinary care teams with motivated staff. Major barriers to ISSPP implementation were a volatile and toxic unregulated drug supply, complicated policy environments, unsustainable funding models, unsupportive regulatory environments, limited medication options, limited physical space, as well as staff shortage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Despite several internal implementation facilitators, ISSPP faced many external and policy-level implementation barriers. Future safer supply programs should be guided by evidence-based planning and implementation, drawing from successful experiences in harm reduction implementation. Implementation facilitators, in particular, evidence-based practice guidelines along with better monitoring of client outcomes can be leveraged to enhance quality of care, address client needs and preferences, and mitigate unintended harms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01177-0","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:52:50Z","timestamp":1745837570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Barriers and facilitators to safer supply pilot program implementation in Canada: a qualitative assessment of service provider perspectives"],"prefix":"10.1186","volume":"22","author":[{"given":"Frishta","family":"Nafeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hyshka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Eeuwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Haywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"1177_CR1","unstructured":"Government of Canada. Opioid- and Stimulant-related Harms in Canada 2024 [cited 2024 Apr 3]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/."},{"key":"1177_CR2","unstructured":"Government of Canada. Interactive Map: Canada's Response to the Opioid Overdose Crisis 2023 [cited 2024 Mar 13]. Available from: https:\/\/health.canada.ca\/en\/health-canada\/services\/drugs-medication\/opioids\/responding-canada-opioid-crisis\/map.html."},{"issue":"9","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247\u201357.","journal-title":"CMAJ"},{"issue":"7","key":"1177_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444\u201350.","journal-title":"Can J Psychiatry"},{"key":"1177_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","volume":"106","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. \u201cCOVID just kind of opened a can of whoop-ass\u201d: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;106: 103742.","journal-title":"Int J Drug Policy"},{"key":"1177_CR6","unstructured":"British Columbia Centre on Substance Use. Risk mitigation in the context of dual health emergencies - interim clinical guidance British Columbia British Columbia Centre on Substance Use; 2022 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/02\/Risk-Mitigation-Guidance-Update-February-2022.pdf."},{"key":"1177_CR7","unstructured":"Canadian Association of People Who Use Drugs. Safe Supply: Concept Document 2019 [cited 2024 May 13]. Available from: https:\/\/vancouver.ca\/files\/cov\/capud-safe-supply-concept-document.pdf."},{"key":"1177_CR8","unstructured":"Government of Canada. Controlled Drugs and Substances Act 2025 [Available from: https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/c-38.8\/page-1.html."},{"key":"1177_CR9","unstructured":"Government of Canada. Health Canada toolkit: COVID-19 and substance use 2024 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/toolkit-substance-use-covid-19.html."},{"key":"1177_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104157","volume":"120","author":"M Karamouzian","year":"2023","unstructured":"Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. Int J Drug Policy. 2023;120: 104157.","journal-title":"Int J Drug Policy"},{"key":"1177_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104339","volume":"125","author":"S Ledlie","year":"2024","unstructured":"Ledlie S, Garg R, Cheng C, Kolla G, Antoniou T, Bouck Z, et al. Prescribed safer opioid supply: a scoping review of the evidence. Int J Drug Policy. 2024;125: 104339.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-022-00614-8","volume":"19","author":"B Lew","year":"2022","unstructured":"Lew B, Bodkin C, Lennox R, O\u2019Shea T, Wiwcharuk G, Turner S. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct J. 2022;19(1):29.","journal-title":"Harm Reduct J"},{"key":"1177_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-023-01219-3","author":"F Nafeh","year":"2023","unstructured":"Nafeh F, Mbichila T, Bouck Z, Scheim A, Mitra S, Bonn M, et al. A preliminary assessment of short-term social and substance use-related outcomes among clients of integrated safer opioid supply pilot programs in Toronto, Canada. Int J Ment Health Addict. 2023. https:\/\/doi.org\/10.1007\/s11469-023-01219-3.","journal-title":"Int J Ment Health Addict."},{"issue":"36","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"E1233","DOI":"10.1503\/cmaj.220892","volume":"194","author":"T Gomes","year":"2022","unstructured":"Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. CMAJ. 2022;194(36):E1233\u201342.","journal-title":"CMAJ"},{"issue":"19","key":"1177_CR15","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1503\/cmaj.221550","volume":"195","author":"G Bardwell","year":"2023","unstructured":"Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T. Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes. CMAJ. 2023;195(19):E668\u201376.","journal-title":"CMAJ"},{"issue":"5","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11524-022-00679-7","volume":"99","author":"A Ivsins","year":"2022","unstructured":"Ivsins A, MacKinnon L, Bowles JM, Slaunwhite A, Bardwell G. Overdose prevention and housing: a qualitative study examining drug use, overdose risk, and access to safer supply in permanent supportive housing in Vancouver, Canada. J Urban Health. 2022;99(5):855\u201364.","journal-title":"J Urban Health"},{"issue":"1","key":"1177_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12954-023-00817-7","volume":"20","author":"M Gagnon","year":"2023","unstructured":"Gagnon M, Rudzinski K, Guta A, Schmidt RA, Kryszajtys DT, Kolla G, et al. Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada. Harm Reduct J. 2023;20(1):81.","journal-title":"Harm Reduct J"},{"issue":"7","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/dar.13745","volume":"42","author":"RA Schmidt","year":"2023","unstructured":"Schmidt RA, Kaminski N, Kryszajtys DT, Rudzinski K, Perri M, Guta A, et al. \u201cI don\u2019t chase drugs as much anymore, and I\u2019m not dead\u201d: client reported outcomes associated with safer opioid supply programs in Ontario. Canada Drug Alcohol Rev. 2023;42(7):1825\u201337.","journal-title":"Canada Drug Alcohol Rev"},{"issue":"1","key":"1177_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","volume":"98","author":"A Ivsins","year":"2021","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. \u201cIt\u2019s Helped Me a Lot, Just Like to Stay Alive\u201d: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J Urban Health. 2021;98(1):59\u201369.","journal-title":"J Urban Health"},{"issue":"1","key":"1177_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13011-024-00598-7","volume":"19","author":"J McCall","year":"2024","unstructured":"McCall J, Hobbs H, Ranger C, Cameron F, Stuart H, Nelken J, et al. Prescribed safer supply during dual public health emergencies: a qualitative study examining service providers perspectives on early implementation. Subst Abuse Treat Prev Policy. 2024;19(1):19.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1177_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104423","volume":"127","author":"L Michaud","year":"2024","unstructured":"Michaud L, Kolla G, Rudzinski K, Guta A. Mapping a moral panic: News media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada. Int J Drug Policy. 2024;127: 104423.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1177_CR22","first-page":"644","volume":"84","author":"E Roberts","year":"2023","unstructured":"Roberts E, Humphreys K. \u201cSafe Supply\u201d initiatives: are they a recipe for harm through reduced health care input and supply-induced toxicity and overdose? JSAD. 2023;84(4):644\u20137.","journal-title":"JSAD"},{"key":"1177_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209341","volume":"161","author":"BB Pauly","year":"2024","unstructured":"Pauly BB, Kurz M, Dale LM, Macevicius C, Kalicum J, P\u00e9rez DG, et al. Implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia: a mixed methods study. J Subst Use Addict Treat. 2024;161: 209341.","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"1177_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13012-023-01331-x","volume":"19","author":"M Kurz","year":"2024","unstructured":"Kurz M, Guerra-Alejos BC, Min JE, Barker B, Pauly B, Urbanoski K, et al. Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia. Implement Sci. 2024;19(1):3.","journal-title":"Implement Sci"},{"issue":"1","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12954-024-00935-w","volume":"21","author":"G Kolla","year":"2024","unstructured":"Kolla G, Tarannum CN, Fajber K, Worku F, Norris K, Long C, et al. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site. Harm Reduct J. 2024;21(1):17.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1177_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12954-023-00789-8","volume":"20","author":"M Mansoor","year":"2023","unstructured":"Mansoor M, Foreman-Mackey A, Ivsins A, Bardwell G. Community partner perspectives on the implementation of a novel safer supply program in Canada: a qualitative study of the MySafe project. Harm Reduct J. 2023;20(1):61.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1177_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13011-022-00494-y","volume":"17","author":"A Foreman-Mackey","year":"2022","unstructured":"Foreman-Mackey A, Pauly B, Ivsins A, Urbanoski K, Mansoor M, Bardwell G. Moving towards a continuum of safer supply options for people who use drugs: a qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada. Subst Abuse Treat Prev Policy. 2022;17(1):66.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1177_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75.","journal-title":"Implement Sci"},{"key":"1177_CR29","unstructured":"Health Canada. Early findings from safer supply pilot projects Canada: Health Canada; 2022 [cited 2024 Apr 3]. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply\/early-findings-safer-supply-pilot-projects\/early-findings-safer-supply-pilot-projects.pdf."},{"issue":"5","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1744987119880234","volume":"25","author":"L Doyle","year":"2020","unstructured":"Doyle L, McCabe C, Keogh B, Brady A, McCann M. An overview of the qualitative descriptive design within nursing research. J Res Nurs. 2020;25(5):443\u201355.","journal-title":"J Res Nurs"},{"issue":"2","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"3","key":"1177_CR32","first-page":"124","volume":"39","author":"JW Creswell","year":"2000","unstructured":"Creswell JW, Miller DL. Determining validity in qualitative inquiry. TIP. 2000;39(3):124\u201330.","journal-title":"TIP"},{"issue":"6","key":"1177_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"1177_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/14659891.2023.2238308","volume":"30","author":"M Haines","year":"2023","unstructured":"Haines M, O\u2019Byrne P. Implementing Safer Supply programs: A comparative case study. J Subst Use. 2023;30(1):24\u20139.","journal-title":"J Subst Use."},{"issue":"6","key":"1177_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11524-012-9698-2","volume":"89","author":"P Fafard","year":"2012","unstructured":"Fafard P. Public health understandings of policy and power: lessons from INSITE. J Urban Health. 2012;89(6):905\u201314.","journal-title":"J Urban Health"},{"issue":"2","key":"1177_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugpo.2005.08.004","volume":"17","author":"D Small","year":"2006","unstructured":"Small D, Palepu A, Tyndall MW. The establishment of North America\u2019s first state sanctioned supervised injection facility: a case study in culture change. Int J Drug Policy. 2006;17(2):73\u201382.","journal-title":"Int J Drug Policy"},{"key":"1177_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103080","volume":"90","author":"E Childs","year":"2021","unstructured":"Childs E, Biello KB, Valente PK, Salhaney P, Biancarelli DL, Olson J, et al. Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: a qualitative study exploring challenges and mitigating strategies. Int J Drug Policy. 2021;90: 103080.","journal-title":"Int J Drug Policy"},{"key":"1177_CR38","unstructured":"National Safer Supply Community of Practice. Prescribed safer supply: Frequently asked questions Canada: National Safer Supply Community of Practice; 2023 [Available from: https:\/\/www.substanceusehealth.ca\/sites\/default\/files\/resources\/2023-05-25-PrescribedSaferSupply_FAQ_NSSCoP.pdf."},{"key":"1177_CR39","unstructured":"National Safer Supply Community of Practice. Emerging evidence brief on prescribed safer supply and client experiences Canada: National Safer Supply Community of Practice; 2023 [cited 2024 May 7]. Available from: https:\/\/pqwchc.org\/wp-content\/uploads\/2023-05-17-PSSEvidenceBrief.pdf."},{"issue":"1","key":"1177_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12954-024-00928-9","volume":"21","author":"H Palis","year":"2024","unstructured":"Palis H, Haywood B, McDougall J, Xavier CG, Desai R, Tobias S, et al. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey. Harm Reduct J. 2024;21(1):5.","journal-title":"Harm Reduct J"},{"key":"1177_CR41","unstructured":"College of Physicians and Surgeons of British Columbia. Access to Prescribed Safer Supply in British Columbia: Policy Direction British Columbia: College of Physicians and Surgeons of British Columbia; 2021 [cited 2024 May 7]. Available from: https:\/\/www.cpsbc.ca\/registrants\/programs\/drug-programs\/sud\/pss."},{"key":"1177_CR42","unstructured":"College of Physicians and Surgeons of Ontario. Safer supply prescribing Ontario: College of Physicians and Surgeons of Ontario; 2020 [cited 2024 May 7]. Available from: https:\/\/dialogue.cpso.on.ca\/2020\/12\/safer-supply-prescribing\/."},{"key":"1177_CR43","unstructured":"British Columbia Centre on Substance Use. Fentanyl patch: Prescribed safer supply protocols British Columbia: British Columbia Centre on Substance Use; 2022 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2024\/04\/Prescribed-Safer-Supply-Protocols-Fentanyl-Patch.pdf."},{"key":"1177_CR44","unstructured":"British Columbia Centre on Substance Use. Fentanyl tablet (PRN program): Prescribed safer supply protocols British Columbia: British Columbia Centre on Substance Use; 2023 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/09\/PSS-Fentanyl-Tablet-PRN.pdf."},{"key":"1177_CR45","unstructured":"British Columbia Centre on Substance Use. Sufentanil: Prescribed safer supply protocols British Columbia: British Columbia Centre on Substance Use; 2023 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/09\/PSS-Protocols-Sufentanil.pdf."},{"key":"1177_CR46","unstructured":"Hales J, Kolla G, Man T, O\u2019Reilly E, Rai N, Sereda A. Safer opioid supply programs (SOS): A harm reduction informed guiding document for primary care teams 2020 [cited 2024 Apr 3]. Available from: https:\/\/docs.google.com\/document\/d\/e\/2PACX-1vTMQEhchBfmTjeBxpDRi6w7pXE5EDuInMiKARuxBcxvFUtjPmqk8l7AFPGYvWn3hOHWkTMo8-m5QPI0\/pub."},{"key":"1177_CR47","unstructured":"Bennett J, Breau C, Ciuman S, Desloges A, Haines M, Hicks T, et al. Safer supply Ottawa (SSO): a harm reduction informed guiding document for primary care teams 2022 [cited 2024 Apr 3]. Available from: https:\/\/safersupplyottawa.com\/wp-content\/uploads\/2022-08-26-Version-Submitted-to-Health-Canada.pdf."},{"key":"1177_CR48","unstructured":"Waraksa M, Bond N, Laurence G, Atkinson K. Safer opioid supply program protocols: Parkdale Queen West Community Health Centre Toronto, Ontario 2022 [cited 2024 Apr 3]. Available from: https:\/\/pqwchc.org\/wp-content\/uploads\/Clinical-and-Operational-Protocols-Parkdale-Queen-West-Community-Health-Centre-June-23-2022.pdf."},{"key":"1177_CR49","unstructured":"British Columbia Office of the Provincial Health Officer. A review of prescribed safer supply programs across British Columbia: Recommendations for future action British Columbia: British Columbia Office of the Provincial Health Officer; 2023 [Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/about-bc-s-health-care-system\/office-of-the-provincial-health-officer\/reports-publications\/special-reports\/a-review-of-prescribed-safer-supply-programs-across-bc.pdf."},{"key":"1177_CR50","unstructured":"Buer LM. Good practices and ethical data collection at harm reduction programs: a breif summary Washington: University of Washington; 2023 [cited 2024 Jun 3]. Available from: https:\/\/bpb-us-e1.wpmucdn.com\/sites.uw.edu\/dist\/a\/19874\/files\/2024\/04\/Ethical-Summary-4_3_2024-Unlinked-07c1ba7ff96ca3f3.pdf."},{"key":"1177_CR51","unstructured":"Javed Z, Burk K, Facente S, Pegram L, Ali A, Asher A. Syringe Services Programs: A Technical Package of Effective Strategies and Approaches for Planning, Design, and Implementation Atlanta: Centers for Disease Control and Prevention; 2020 [cited 2024 Jun 3]. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/105304."},{"key":"1177_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108202","volume":"216","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend. 2020;216: 108202.","journal-title":"Drug Alcohol Depend"},{"key":"1177_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103849","volume":"110","author":"B Pauly","year":"2022","unstructured":"Pauly B, McCall J, Cameron F, Stuart H, Hobbs H, Sullivan G, et al. A concept mapping study of service user design of safer supply as an alternative to the illicit drug market. Int J Drug Policy. 2022;110: 103849.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1177_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","volume":"20","author":"M Haines","year":"2023","unstructured":"Haines M, O\u2019Byrne P. Safer opioid supply: qualitative program evaluation. Harm Reduct J. 2023;20(1):53.","journal-title":"Harm Reduct J"},{"key":"1177_CR55","doi-asserted-by":"crossref","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B, Crabtree A, Bach P, Krebs E, Dale L, Meilleur L. Effect of Risk Mitigation Guidance for opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. bmj. 2024;384.","DOI":"10.1136\/bmj-2023-076336"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01177-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:05:44Z","timestamp":1759763144000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01177-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01177-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author affiliations are revised.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Unity Health Toronto Research Ethics Board (Project #21\u2013273). Informed consent was obtained from all participants prior to commencing interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented for de-identified quotes to be used for scientific manuscripts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HH and CM are employed by one of the pilot programs under evaluation. MB grants and personal fees from AbbVie and Gilead Sciences, outside of the submitted work. MB has also worked for the Canadian Association of People Who Use Drugs which receives funds from Health Canada. Other authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}